Published in J Immunol on May 01, 1992
Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med (1995) 2.62
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci U S A (2008) 1.63
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J Clin Invest (1999) 1.23
Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev (2009) 1.19
Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol (2007) 1.16
A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano (2014) 1.16
Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. J Autoimmun (2006) 1.13
Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease. Methods Mol Biol (2012) 1.11
Distribution of the integral plasma membrane glycoprotein CE9 (MRC OX-47) among rat tissues and its induction by diverse stimuli of metabolic activation. Biochem J (1995) 1.03
Targeting dendritic cells to treat multiple sclerosis. Nat Rev Neurol (2010) 1.02
Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J Autoimmun (2012) 1.01
Intrinsic and induced regulation of the age-associated onset of spontaneous experimental autoimmune encephalomyelitis. J Immunol (2008) 0.98
Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis. Results Probl Cell Differ (2010) 0.96
Prevention of allograft rejection by amplification of Foxp3(+)CD4(+)CD25(+) regulatory T cells. Transl Res (2008) 0.91
Experimental Autoimmune Encephalomyelitis in Mice. Methods Mol Biol (2016) 0.86
Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo. J Neuroinflammation (2013) 0.85
Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes. Rev Diabet Stud (2012) 0.83
Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune disease. Adv Exp Med Biol (2008) 0.82
Active suppression of 1-fluoro-2,4-dinitrobenzene-immune T cells. Requirement of an auxiliary T cell induced by antigen. J Exp Med (1979) 3.35
CTLA-4: a negative regulator of autoimmune disease. J Exp Med (1996) 3.25
Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol (1997) 2.89
Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med (1995) 2.62
An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol (1995) 2.52
Inhibition of specific immune responses by feeding protein antigens. IV. Evidence for tolerance and specific active suppression of cell-mediated immune responses to ovalbumin. J Immunol (1979) 2.29
CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity (1996) 2.11
Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol (1994) 2.10
The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med (1979) 2.09
Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the H-2D region: correlation with TEMV-specific delayed-type hypersensitivity. J Immunol (1985) 2.06
Monocytes/macrophages isolated from the mouse central nervous system contain infectious Theiler's murine encephalomyelitis virus (TMEV). Virology (1990) 1.90
Immune suppression with supraoptimal doses of antigen in contact sensitivity. I. Demonstration of suppressor cells and their sensitivity to cyclophosphamide. J Immunol (1977) 1.87
A splenic requirement for the generation of suppressor T cells. J Immunol (1977) 1.86
Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol (2000) 1.76
Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs. J Immunol (1986) 1.76
Suppressive mechanisms involving sensitization and tolerance in contact allergy. Immunol Rev (1980) 1.72
Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med (2001) 1.70
The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J Immunol (1976) 1.68
Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci (2008) 1.66
The induction of hapten-specific T cell tolerance using hapten-modified lymphoid membranes. II. Relative roles of suppressor T cells and clone inhibition in the tolerant state. Eur J Immunol (1977) 1.66
Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol (1998) 1.59
Structured interview data on 102 cases of multiple personality disorder from four centers. Am J Psychiatry (1990) 1.56
Interferon gamma induction during oral tolerance reduces T-cell migration to sites of inflammation. Gastroenterology (2000) 1.55
Control of experimental contact sensitivity. Adv Immunol (1980) 1.54
Community-acquired pneumonia due to penicillin-resistant pneumococci. N Engl J Med (1985) 1.54
Class I-deficient resistant mice intracerebrally inoculated with Theiler's virus show an increased T cell response to viral antigens and susceptibility to demyelination. Eur J Immunol (1993) 1.53
The role of infections in autoimmune disease. Clin Exp Immunol (2009) 1.47
The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev (1998) 1.43
First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection. Am J Transplant (2014) 1.41
Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol (1992) 1.41
A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol (2000) 1.40
The 5' noncoding sequences from a less virulent Theiler's virus dramatically attenuate GDVII neurovirulence. J Virol (1991) 1.37
Correlation of lymphocyte transformation with tuberculin skin-test sensitivity. Am Rev Respir Dis (1973) 1.36
Accuracy of clinical diagnosis of genital ulcer disease. Sex Transm Dis (1991) 1.35
Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol (1990) 1.34
Epitope spreading. Curr Opin Immunol (1996) 1.34
Direct activation of innate and antigen-presenting functions of microglia following infection with Theiler's virus. J Virol (2001) 1.34
Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest (2001) 1.32
Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol (1995) 1.31
Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol (1998) 1.31
Suppressor T cell mechanisms in contact sensitivity. I. Efferent blockade by syninduced suppressor T cells. J Immunol (1978) 1.31
A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest (2001) 1.31
Differential permeability of the BBB in acute EAE: enhanced transport of TNT-alpha. Am J Physiol (1996) 1.26
Edge-light pupil cycle time. Br J Ophthalmol (1978) 1.25
Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. Eur J Immunol (1993) 1.24
Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. II. Survey of host immune responses and central nervous system virus titers in inbred mouse strains. Microb Pathog (1987) 1.24
Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J Clin Invest (1999) 1.23
Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest (1999) 1.22
Temporal development of autoreactive Th1 responses and endogenous presentation of self myelin epitopes by central nervous system-resident APCs in Theiler's virus-infected mice. J Immunol (2000) 1.22
A novel technique for management of the en bloc bladder cuff and distal ureter during laparoscopic nephroureterectomy. J Urol (1999) 1.20
H-2 restriction of suppressor T-cell induction by hapten-modified lymphoid cells in tolerance to 1-fluoro-2,4-dinitrobenzene contact sensitization. J Exp Med (1977) 1.20
Clostridium difficile colitis associated with the use of antineoplastic agents. Eur J Clin Microbiol (1984) 1.20
Tolerance: two pathways of negative immunoregulation in contact sensitivity to DNFB. Cold Spring Harb Symp Quant Biol (1977) 1.19
Ectopia of the vas deferens. Pediatr Radiol (1995) 1.17
Requirements for induction of T cell tolerance to DNFB: efficiency of membrane-associated DNFB. J Immunol (1976) 1.16
Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol (2000) 1.16
Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J Interferon Cytokine Res (1998) 1.15
In vivo effects of GK1.5 (anti-L3T4a) monoclonal antibody on induction and expression of delayed-type hypersensitivity. Cell Immunol (1985) 1.15
Risk of infection after open fracture of the arm or leg. Arch Surg (1988) 1.14
The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J Immunol (1997) 1.12
Posterior transvertebral osteotomy for adult thoracolumbar kyphosis. Spine (Phila Pa 1976) (1994) 1.11
Alterations of murine immunologic responses after silica dust inhalation. J Immunol (1974) 1.11
Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to Theiler's virus-induced demyelinating disease. J Immunol (1995) 1.11
Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis (1993) 1.11
Flow cytometric and functional analyses of central nervous system-infiltrating cells in SJL/J mice with Theiler's virus-induced demyelinating disease. Evidence for a CD4+ T cell-mediated pathology. J Immunol (1996) 1.10
Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc Res Tech (1995) 1.10
CD8-deficient SJL mice display enhanced susceptibility to Theiler's virus infection and increased demyelinating pathology. J Neurovirol (2001) 1.10
Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol (2001) 1.10
Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J Immunol (1991) 1.09
Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction. J Immunol (1995) 1.09
Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics (2000) 1.08
Cerebral phaeohyphomycosis caused by Xylohypha bantiana. Eur J Clin Microbiol Infect Dis (1989) 1.07
IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J Immunol (1997) 1.07
Specific immune regulation of chronic-relapsing experimental allergic encephalomyelitis in mice. J Immunol (1988) 1.06
Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. III. Failure of neuroantigen-specific immune tolerance to affect the clinical course of demyelination. J Neuroimmunol (1990) 1.06
Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J Immunol (1990) 1.04
99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol (2010) 1.03
Anergy in vivo: down-regulation of antigen-specific CD4+ Th1 but not Th2 cytokine responses. Int Immunol (1994) 1.03
Antimicrobial susceptibility of Haemophilus ducreyi. Antimicrob Agents Chemother (1990) 1.03
Atrial fibrillation associated with autonomic dysreflexia. Am J Phys Med Rehabil (1991) 1.02
Iron and CF-related anemia: expanding clinical and biochemical relationships. Pediatr Pulmonol (2010) 1.02
Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J Clin Invest (2000) 1.02
Cardiac antigen-specific autoantibody production is associated with cardiomyopathy in Trypanosoma cruzi-infected mice. J Immunol (1994) 1.02
Inhibition of specific immune responses by feeding protein antigens. V. Induction of the tolerant state in the absence of specific suppressor T cells. J Immunol (1982) 1.01
Suppressor T cell circuits in contact sensitivity. I. Two mechanistically distinct waves of suppressor T cells occur in mice tolerized with syngeneic DNP-modified lymphoid cells. J Immunol (1982) 1.01
Central nervous system chemokine expression during Theiler's virus-induced demyelinating disease. J Neurovirol (1999) 1.01
Mutation of a major histocompatibility class I locus, H-2D, leads to an increased virus burden and disease susceptibility in Theiler's virus-induced demyelinating disease. J Neurovirol (1995) 1.01
Cytokines as intrinsic and exogenous regulators of pathogenesis in experimental autoimmune encephalomyelitis. Res Immunol (1999) 1.00
Identification of a locus on mouse chromosome 3 involved in differential susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Virol (1990) 1.00
Enhanced susceptibility to Theiler's virus-induced demyelinating disease in perforin-deficient mice. J Neuroimmunol (2001) 1.00
A simple medium for the primary isolation of Haemophilus ducreyi. Eur J Clin Microbiol Infect Dis (1992) 1.00
Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol (1995) 1.00
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun (2000) 0.98
Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis. J Immunol (1998) 0.98